Market Overview

Immunomedics Announces Preclinical Study Showed Epratuzumab's B-Cell Modulation Effect Elucidated

Related IMMU
Immunomedics Reports Preliminary Results From Pretargeted Imaging Study in Patients With Metastatic Breast Cancer
Immunomedics Announces Expanded Phase 1/2 Trials Which Confirm Activity, Good Safety Profile of IMMU-132

Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body.

Posted-In: News FDA


Related Articles (IMMU)

Around the Web, We're Loving...

Get Benzinga's Newsletters